سعر جلوفيلدان 50 مجم 2022

Gluvildan 50 mg tablets (vildagliptin) by Pharco (Egypt).

• Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes: as monotherapy when metformin inappropriate, or in combination with other antidiabetic medicines including insulin when control is inadequate.Population: Adults with type 2 diabeteseMC / MHRA

• Common: dizziness, headache, tremor, nausea, constipation, diarrhoea, abdominal pain, hyperhidrosis, rash, arthralgia, myalgia, asthenia, peripheral oedema. Rare: pancreatitis. Not known: hepatitis, bullous lesions.International label, same formulation · eMC / MHRA

• Hypersensitivity to the active substance or to any of the excipients.International label, same formulation · eMC / MHRA

• Not a substitute for insulin; do not use in type 1 diabetes or DKA. Do not use in hepatic impairment (including ALT/AST >3× ULN). Monitor LFTs before treatment, every 3 months in year 1, then periodically. Risk of acute pancreatitis; skin lesions reported; caution in NYHA IV HF (no experience). With sulphonylurea, hypoglycaemia risk — consider lower SU dose. Contains lactose.International label, same formulation · eMC / MHRA

• ACE inhibitorsModeratePossible increased risk of angioedema when combined with ACE inhibitors.eMC / MHRA
• Thiazides, corticosteroids, thyroid products, sympathomimeticsModerateMay reduce the hypoglycaemic effect of vildagliptin.eMC / MHRA

• No adequate human data; animal reproductive toxicity at high doses. Should not be used during pregnancy.International label, same formulation · eMC / MHRA
• Unknown if excreted in human milk; excreted in animal milk. Should not be used during breast-feeding.International label, same formulation · eMC / MHRA

English text not available for this section.